hospira inc (HSP) Key Developments
Hospira Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Jul 29 15
Hospira Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of $1,183.6 million against $1,135.8 million a year ago. Income from operations was $218.6 million against $99.5 million a year ago. Income before income taxes was $206.0 million against $81.1 million a year ago. Net income was $145.1 million against $70.9 million a year ago. Earnings per share diluted were $0.82 against $0.42 per share a year ago. Adjusted net income from operations was $226.9 million against $179.3 million a year ago. Adjusted net income was $150.2 million against $122.1 million a year ago. Adjusted diluted earnings per share were $0.85 against $0.72 per share a year ago.
For the six months, the company reported net sales of $2,358.5 million against $2,186.6 million a year ago. Income from operations was $352.0 million against $199.1 million a year ago. Income before income taxes was $327.9 million against $162.2 million a year ago. Net income was $220.7 million against $138.8 million a year ago. Earnings per share diluted were $1.26 against $0.82 per share a year ago. Adjusted net income from operations was $474.1 million against $330.8 million a year ago. Adjusted net income was $320.3 million against $223.8 million a year ago. Adjusted diluted earnings per share were $1.82 against $1.32 per share a year ago. Net cash provided by operating activities was $186.2 million against $175.5 million a year ago. Capital expenditures was $221.4 million against $184.8 million a year ago.
Hospira Launches of Generic Bivalirudin for Injection
Jul 16 15
Hospira announced that it had obtained U.S. Food and Drug Administration approval for the launch of bivalirudin for injection, a generic version of The Medicines Company's Angiomax. Hospira's bivalirudin for injection is available in a single-dose flip-top vial, which matches the current branded offering available. Additionally, the company plans to launch a differentiated presentation of the 250 mg bivalirudin for injection in Hospira's unique ADD-Vantage vial. Hospira's bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA); patients undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI); and patients with, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), undergoing PCI. Bivalirudin is intended for use with aspirin.
Hospira Inc. to Report Q2, 2015 Results on Jul 29, 2015
Jul 15 15
Hospira Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Jul 29, 2015
US Court of Appeals for the Federal Circuit Court Rules against The Medicines Company in its Angiomax Patent Litigation with Hospira, Inc
Jul 8 15
The Medicines Company has announced that the US Court of Appeals for the Federal Circuit Court has ruled against the company in its Angiomax, or bivalirudin, patent litigation with Hospira Inc. In its ruling on July 8, 2015, the Federal Circuit held that US Patent Nos. 7,582,727 and 7,598,343 are invalid. On March 31, 2014, the US District Court of Delaware found that all of the asserted claims of the '727 patent and the '343 patent covering Angiomax were valid but not infringed by Hospira's ANDA products. The Medicines Company appealed the District Court's claim construction and non-infringement rulings, while Hospira appealed the validity rulings.
Assistance Publique-Hospitaux de Paris Reaches an Agreement with Hospira to Supply the Biosimilar Inflectra
Jul 7 15
Assistance Publique-Hospitaux de Paris reached an agreement with Hospira to supply the biosimilar Inflectra (infliximab), which is indicated for the treatment of rheumatoid arthritis, Crohn's disease, and psoriasis. It has secured a 45% price discount compared to Remicade. The contract is reported to be worth an estimated USD 6.6 million per annum. The 45% price discount would be less than the 72% price reduction that Norway secured for Remsima, another biosimilar version of Remicade. There is no indication of what pricing level levels where offered by other biosimilar manufacturers in the negotiations with the AP-HP.